ALLK תחזית צמיחת רווח נקי למניה לשנה הבאה Allakos Inc

Allakos Inc. relies on stable demand in chronic allergy therapy thanks to the patent protection of its formulas. The n+1 net income per share growth projection on GURU.Markets reflects the current business adaptation, where the value is fixed at 36.80. Lirentelimab trials are driving growth, although management is currently optimizing headcount and updating the R&D strategy to restore the confidence of institutional investors.

This indicator reflects the consensus forecast for the average annual earnings growth over the coming twelve-month period, allowing for an assessment of the fundamental capitalization potential through future cash flows. By analyzing the valuation of forward net income growth rates, an investor can align market expectations with the progress in updating the immunological portfolio of Allakos Inc. (ALLK), which is critical for restoring confidence following past clinical failures.